Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
Main Author: | Nae-Yun Heo |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2017-06-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2017-0106.pdf |
Similar Items
-
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01) -
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01) -
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01) -
Elevated alanine aminotransferase and low aspartate aminotransferase/alanine aminotransferase ratio are associated with chronic kidney disease among middle-aged women: a cross-sectional study
by: Hirotaka Ochiai, et al.
Published: (2020-11-01) -
Eating quickly is associated with a low aspartate aminotransferase to alanine aminotransferase ratio in middle-aged adults: a large-scale cross-sectional survey in Japan
by: Eri Ozaki, et al.
Published: (2020-10-01)